|
Filariasis IgG/IgM Combo Rapid Test kits/medical/laboratory/healthcare diagnosis
|
INTENDED USE The Filariasis IgG/IgM Combo Rapid Test is a lateral flow immunoassay for the simultaneous detection and differentiation of IgG and IgM antilymphatic filarial parasites (W. Bancrofti and B. Malayi) in human serum, plasma or whole blood. This test is intended to be used as a screening test and as an aid in the diagnosis of infection with lymphatic filarial parasites. Any reactive specimen with the Filariasis IgG/IgM Combo Rapid Test must be confirmed with alternative testing method(s).
INTRODUCTION The lymphatic filariasis known as Elephantiasis, mainly caused by W. bancrofti and B. malayi, affects about 120 million people over 80 countries1,2. The disease is transmitted to humans by the bites of infected mosquitoes within which the microflariae sucked from an infected human subject develops into third-stage larvae. Generally, repeated and prolonged exposure to infected larvae is required for establishment of human infection.
The definitive parasitologic diagnosis is the demonstration of microflariae in blood samples3. However, this gold standard test is restricted by the requirement for nocturnal blood collection and lack of adequate sensitivity. Detection of circulating antigens is commercially available. Its usefulness is limited for W. bancrofti4. In addition, microfilaremia and antigenemia develop from months to years after exposure.
Antibody detection provides an early means to detect filarial parasite infection. Presence of IgM to the parasite antigens suggest current infection, whereas, IgG corresponds to late stage of infection or past infection5. Furthermore, identification of conserved antigens allows ‘pan-filaria’ test to be applicable. Utilization of recombinant proteins eliminates cross-reaction with individuals having other parasitic diseases6. The Filariasis IgG/IgM Combo Rapid Test uses conserved recombinant antigens to simultaneously detect IgG and IgM to the W. bancrofti and B. malayi parasites without the restriction on specimen collection.
KIT COMPONENTS 1.Each kit contains 30 test devices, each sealed in a foil pouch with three items inside: a. One cassette device. b. One plastic dropper. c. One desiccant. 2.Sample diluent (1 bottle, 5 mL) 3.One package insert (instruction for use).
PROCEDURE Step 1: Bring the specimen and test components to room temperature if refrigerated or frozen. Mix the specimen well prior to assay once thawed. Step 2: When ready to test, open the pouch at the notch and remove device. Place the test device on a clean, flat surface. Step 3: Be sure to label the device with specimen’s ID number. Step 4: For whole blood test
Apply 1 drop of whole blood (about 40-50 µL) into the sample well.
Then add 1 drop (about 35-50 µL) of Sample Diluent immediately.

1 drop of specimen 1 drop of sample diluent 15 minutes
Step 5: Set up timer.
Step 6: Results can be read in 15 minutes. Positive results can be visible in as short as 1 minute.
Don’t read result after 15 minutes. To avoid confusion, discard the test device after interpreting the result.
 
PERFORMANCE CHARACTERISTICS
1. Clinical Performance For IgM Test 24 samples from patients with acute lymphatic filariasis and 200 samples collected from a non-filariasis region were tested by the Filariasis IgG/IgM Combo Rapid Test.
Comparison for all subjects is showed in the following table:
|
|
Filariasis IgG/IgM Combo Rapid Test |
|
|
Clinical Status |
Positive |
Negative |
Total |
|
Acute filariasis |
23 |
1 |
24 |
|
Negative |
0 |
200 |
200 |
|
Total |
23 |
201 |
224 |
Relative Sensitivity: 95.8%; Relative Specificity:100%; Overall agreement: 99.6%
2. Clinical Performance For IgG Test
26 samples from patients with chronic lymphatic filariasis and 200 samples collected from a non-filariasis region were tested by the Filariasis IgG/IgM Combo Rapid Test. Comparison for all subjects is
showed in the following table:
|
|
Filariasis IgG/IgM Combo Rapid Test |
|
|
Clinical Status |
Positive |
Negative |
Total |
|
Chronic filariasis |
24 |
2 |
26 |
|
Negative |
0 |
200 |
200 |
|
Total |
24 |
202 |
226 | Relative Sensitivity: 92.3%; Relative Specificity:100%; Overall agreement: 99.1%bio-equip.cn
Zhuhai Encode Medical Engineering Co.,Ltd (herinafter referred to as Encode) was established in 1994, as one of the earliest
and largest manufacturers of in-vitro diagnostic field in China. Encode specializes in R&D, production and distribution of in-vitro diagnostic products. As a hi-tech and innovative enterprise, we have researched and developed series of microbiological diagnostic productds and immunology diagnostic rapid tests, which are used for diagnosis of infection disease, cardiac markers, tumor markers, fertility test, durgs of abuse and sexual transmitted disease.
Encode occupies a land of 15,000 m2 in Zhuhai. There are 2,000 GMP standard clean workshops of microbiology diagnostic products, colloidal gold diagnostic products and molecular with automatic manufacturing lines and passed the quality management system evaluation by SFDA and GDFDA.
Encode has established extensive cooperation with research centers in universtities, such as Lanzhou University, South China University of Technology, Jinan University and Shanghai Plumonary Hospital, etc. Whith strong R&D and technological innovation capability. Encode ranks leading level in terms of IVD industries field in China. We have also obtained ISO 13485:2003, ISO 9001:2001, CE and have been granted the title of national hi-tech enterprise.
Today, we provide medical products and health care solution to clients not only in China, but also worldwide, such as Europe, Africa, Middle East, South East, Asia etc.
With the experience and dedication of the scientific staffs, Zhuhai Encode Medical Engineering Co.,Ltd will continue our endeavor to provide professional in-vitro diagnostic products and health care solutions to the worldwide and make our contributions to the career of human health.
|
|
|